2024-518019-20-00招募中2 期
Effects of mesenchymal stem cells administration on organ failure during septic shock: Phase II randomized comprator-controlled study CHOC-MSC
CHRU De Nancy1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2024年12月6日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- The primary endpoint is the SOFA score (clinico-biological severity score ranging from 0 to 24 points) at D7 (or the day of death or discharge from intensive care if before D7) compared with that observed in patients in the control group.
研究概览
简要总结
The main objective is to determine the effect of MSC administered in the early phase of septic shock on the evolution of organ failure as judged by the SOFA (Sepsis Organ Failure Assessment score) at D7 (or on the day of death or discharge from intensive care if before D7) compared with that observed in patients in the control group.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •1-Patient aged 18 or over, For women under 60: Presence of a negative HCG test. CTFG recommendations (Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1) must be followed. Effective methods of contraception must be used until the end of the clinical trial (J90).
- •2-Presence of community-acquired septic shock for less than 24 hours. The time of onset of septic shock is defined as the time of introduction of catecholamines With at least 2 organ failures other than hemodynamic (Respiratory: PaO2/FiO2 < 300 if mechanical ventilation or Respiratory rate > 24 if spontaneous ventilation; Neurological: Glasgow score < 13; Renal: oliguria < 0.5ml/kg/h for more than 4 hours or acute renal failure with creatininemia >20mg/L , Hematological: platelets < 100000/mm3 ; and/or Hepatic: bilirubinemia > 34 micromol/L)
- •3- Septic shock occurring between Sunday 5.00 pm and Friday 10.00 am (for reasons of availability of the CTU staff responsible for preparing the drug for the clinical trial).
- •4- Patient who has given consent or for whom consent has been obtained from a close relative/trusted person if applicable or inclusion in immediate life-threatening emergency situation if applicable
- •5-Person affiliated to a Social Security scheme or beneficiary of such a scheme.
排除标准
- •Non-septic shock
- •Persons referred to in Articles 10, 31, 32, 33 and 34 of Regulation EU 536/
- •Pregnant woman, parturient or breastfeeding mother Minor person (not emancipated) Persons deprived of liberty (6) by a judicial decision or Major person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) Major person unable to express consent
- •Nosocomial septic shock
- •Immunosuppression: current immunosuppressive therapy (including corticosteroid therapy > 20 mg prednisolone equivalent), solid tumor active or in remission for less than 5 years, hematological cancer, asplenia.
- •Rapport PaO2/FiO2 < 100
- •Encephalic death
- •Moribund patient
- •Existence of immediate therapeutic limitations
- •Patient included in another interventional therapeutic trial in progress or less than 30 days old
- •Known hypersensitivity to albumin or to one of the excipients (caprylic acid or sodium caprylate).
结局指标
主要结局
The primary endpoint is the SOFA score (clinico-biological severity score ranging from 0 to 24 points) at D7 (or the day of death or discharge from intensive care if before D7) compared with that observed in patients in the control group.
The primary endpoint is the SOFA score (clinico-biological severity score ranging from 0 to 24 points) at D7 (or the day of death or discharge from intensive care if before D7) compared with that observed in patients in the control group.
次要结局
- For objective 1: Time to SOFA < 3 (in days). Start date = date of arrival in the intensive care unit, end date = D7.
- For the 2nd objective: i) Number of days living without respiratory assistance at D28, ii) Number of days living without catecholamines at D28, iii) Number of days living without extra-renal purification at D28, iv) Length of stay in intensive care and in hospital,
- For the 3rd objective: i) mortality at D28, ii) mortality at D90
- For the 4th objective i) Transient fall in PaO2/FiO2 ratio (or arterial desaturation >5%) within 2 hours of MSC administration ii) Transient rise in mean pulmonary arterial pressure (>5 mHg) within 2 hours of MSC administration iii) Shivering, hyperthermia within 2 hours of MSC administration iv) occurrence of pulmonary embolism within 2 hours of MSC administration v) occurrence of adverse events up to 90 days after MSC injection.
研究者
Sébastien GIBOT
Scientific
CHRU De Nancy
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Remote Ischemic Postconditioning in Septic ShockNCT07273942Hospices Civils de Lyon720
Unknown
不适用
Treatment of Severe Infections With Mesenchymal Stem CellsSeptic ShockNCT02883803Central Hospital, Nancy, France66
招募中
2 期
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic ShockPathologic ProcessesShockInflammationInfectionsSepsisSeptic ShockSystemic Inflammatory Response SyndromeNCT05969275Ottawa Hospital Research Institute296
尚未招募
不适用
Adult stem cell transplantation in severe blood poisining.Mesenchymal stromal cellSeptic shockInfectionInflammationNL-OMON26490Erasmus Medical Center Rotterdam30
招募中
1 期
Mesenchymal stromal cell therapy for rehabilitation after hip fracture.2024-517010-15-01Karolinska University Hospital10